Details for Patent: 8,795,723

Title:	Sustained drug release compositions
Abstract:	The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.
Inventor(s):	Gervais; Sonia (Laval, CA), Smith; Damon (Saint-Laurent, CA), Contamin; Pauline (Magny en Vexin, FR), Ouzerourou; Rachid (Anjou, CA), Ma; My Linh (Saint-Laurent, CA)
Assignee:	Angelini Pharma Inc. (Gaithersburg, MD)
Filing Date:	Sep 11, 2006
Application Number:	11/519,189
Claims:	1. A solid, monolithic sustained release pharmaceutical composition, the composition comprising: a. a sustained release matrix comprising a score that permits the composition to be broken along the score to produce at least two subunits each having a new solvent accessible surface where at least one subunit and an intact form of the pharmaceutical composition have dissolution profiles that have a similarity factor of at least 50%, wherein the matrix comprises from about 20% to about 60% by weight of cross-linked high amylose starch; and b. an effective amount of trazodone or a pharmaceutically acceptable salt thereof disposed within the matrix, wherein the composition (i) has a hardness of from about 100 N to about 350 N, (ii) displays substantially the same release kinetics when the composition is broken to create a new solvent accessible surface, and (iii) is in the form of a tablet. 2. The composition of claim 1, wherein the composition, when administered to a mammal, achieves an effective plasma concentration of the trazodone from at least about 1 hour to at least about 24 hours after initial administration. 3. The composition of claim 1, wherein at least one of the subunits has substantially the same release kinetics of the active agent as the intact composition from which it was derived. 4. The composition of claim 1, wherein the similarity factor is at least 55%. 5. A solid, monolithic sustained release pharmaceutical composition comprising: a. a sustained release matrix comprising a score that permits the composition to be broken along the score to produce at least two subunits each having a new solvent accessible surface where at least one subunit and an intact form of the pharmaceutical composition have dissolution profiles that have a similarity factor of at least 50%, wherein the matrix comprises from about 20% to about 60% by weight of cross-linked high amylose starch; and b. an effective amount of trazodone or a pharmaceutically acceptable salt thereof disposed within the matrix, wherein the composition (i) has a hardness of from about 100 N to about 350 N, (ii) can be divided into at least two subunits where each subunit releases the active agent with substantially the same release profile as the composition from which it was derived, and (iii) is in the form of a tablet. 6. The composition of claim 5, wherein the composition has a hardness in the range of from about 100 N to about 180 N. 7. The composition of claim 5, wherein the similarity factor is at least 55%. 8. The composition of claim 1, wherein the new solvent accessible surface is capable of forming a barrier upon contact with a solvent. 9. The composition of claim 1, wherein the subunits and the intact composition from which they are derived are bioequivalent. 10. The composition of claim 1, comprising from about 15% to about 60% by weight of the trazodone or the pharmaceutically acceptable salt thereof disposed within the matrix. 11. The composition of claim 10 comprising from about 20% to about 50% by weight of the trazodone or the pharmaceutically acceptable salt thereof and from about 20% to about 50% by weight of the starch. 12. The composition of claim 11 comprising from about 35% to about 50% by weight of the trazodone or the pharmaceutically acceptable salt thereof and from about 20% to about 50% by weight of the starch. 13. The composition of claim 1, wherein the starch is crosslinked with phosphorus oxychloride. 14. The composition of claim 13, wherein the starch comprises hydroxypropyl side chains. 15. The composition of claim 1 further comprising a pharmaceutical additive. 16. The composition of claim 15, wherein the pharmaceutical additive is selected from the group consisting of a binding agent, a solubilizing agent, an acidifying agent, a pore forming agents, a lubricant, and a glidant. 17. The composition of claim 16, wherein the binding agent is hydroxypropylmethylcellulose. 18. The composition of claim 16, wherein the lubricant is sodium stearyl fumarate. 19. The composition of claim 16, wherein the glidant is colloidal silicon dioxide. 20. The composition of claim 1, wherein the tablet is in the form of a caplet. 21. A method of treating a mammal, the method comprising administering to the mammal the composition of claim 1. 22. The composition of claim 5, wherein each subunit releases the trazodone or the pharmaceutically acceptable salt thereof for about 12 hours. 23. The composition of claim 5, wherein each subunit releases the trazodone or the pharmaceutically acceptable salt thereof for about 18 hours. 24. The composition of claim 5, wherein each subunit releases the trazodone or the pharmaceutically acceptable salt thereof for about 24 hours. 25. The composition of claim 1, wherein the composition has a hardness in the range of from about 100 N to about 180 N. 26. The composition of claim 5, wherein the tablet is in the form of a caplet. 27. A method of treating a mammal, the method comprising administering to the mammal the composition of claim 5.